Orchestra BioMed Hldgs Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $778.00K Beat $750.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Orchestra BioMed Holdings (NASDAQ:OBIO) reported Q2 EPS of $(0.45), missing the $(0.39) estimate, and sales of $778K, beating the $750K estimate. EPS decreased by 28.57% YoY, while sales decreased by 14.97% YoY.
August 12, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Orchestra BioMed Holdings reported a Q2 EPS of $(0.45), missing the $(0.39) estimate, and sales of $778K, beating the $750K estimate. EPS decreased by 28.57% YoY, while sales decreased by 14.97% YoY.
The missed EPS estimate and significant YoY decrease in EPS are likely to negatively impact OBIO's stock price in the short term, despite the slight beat in sales estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100